• No results found

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

N/A
N/A
Protected

Academic year: 2021

Share "NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE"

Copied!
5
0
0

Loading.... (view fulltext now)

Full text

(1)

NATIONAL INSTITUTE FOR HEALTH AND CARE

EXCELLENCE

Medical Technologies Advisory Committee (MTAC)

Minutes of the 49th meeting on 19 March 2015

Level1A City Tower, Piccadilly Plaza, Manchester M1 4BT

Committee Present: Professor Bruce Campbell (Chair) Ms Susan Bennett

Professor Nigel Brunskill Mr Matthew Campbell – Hill Professor Daniel Clark Dr Fiona Denison Dr Jerry Hutchinson

Professor Mohammad Ilyas Dr Cynthia Iglesias Dr Greg Irving Dr Eva Kaltenthaler Dr Paul Knox Dr Rory O’Connor Mr Brian Selman

Professor Wendy Tindale Professor Allan Wailoo

Committee Apologies: Dr Peter Groves (Vice Chair) Professor Tony Freemont Mrs Karen Partington Dr Janelle Yorke

Mr Andrew Chukwuemeka Professor Shaheen Hamdy Mr John Wilkinson

Dr Amber Young

MTEP staff in attendance: Mirella Marlow, Programme Director Bernice Dillon, Technical Adviser Chris Pomfrett, Technical Adviser Lee Dobson, Programme Manager Joanne Higgins, Technical Analyst Paul Dimmock, Technical Analyst Neil Hewitt, Technical Analyst Liesl Miller, Technical Analyst

Kimberley Carter, Technical Analyst Harriet Unsworth, Technical Analyst Marlon Hope, Project Manager Joanne Heaney, Coordinator

Jessica Linville-Boud, Project Manager Izabela Syrek, Administrator

(2)

External Assessment Centre Representatives:

Dr Grace Caroline-Rees, Director, Cedar Dr Alistair Ray, Health Economist, Cedar

Expert Advisors: Mr Andrew Thorpe, Consultant in Urology, Freeman Hospital, The Newcastle Upon Tyne NHS Fondation Trust (in person) Dr Neil Barber, Consultant Urologist, Frimley Park Hospotal, Frimley Health NHS Foundation Trust (by phone)

Professor Nicola Maffuli, Consultant Trauma and Orthopaedic Surgeon, Barts and the London Hospital / Newham University Hospital in London (by phone)

Mr Maneesh Bhatia, Consultant Orthopaedic Surgeon, Leicester General Hospital, University Hospitals of Leicester NHS Trust (by phone)

Mr Sajjad Ahmad, Honorary Consultant Ophthalmologist, Royal Liverpool University Hospital, The Royal Liverpool and

Broadgreen University Hospital NHS Trust (by phone)

Ms Joy Tickle, Tissue Viability Nurse Specialist, Shropshire Community Health NHS Trust (by phone)

Mr Ray Norris, Tissue Viability Nurse and Medical Practice Consultant, Brentwood Community Hospital, North East London NHS Foundation Trust (by phone)

Professor Venkataraman Subramanian, Clinical Associate Professor and Honorary Consultant in Gastroenterology, St James University Hospital, Leeds Teaching Hospitals NHS Trust (by phone)

Dr James East, Consultant Gastroenterologist & Endoscopist, John Radcliffe Hospital , Oxford University Hospitals NHS Trust (by phone)

Observing: Brian O’Toole, Health Economist, Healthcare Improvement

Scotland

Heather Stephens, Technology Implementation Manager, HTAP, NICE

Rachel Adams, Information Specialist, Guidance Information Services, NICE

Jae Long, Assistant Project Manager, HTAP, NICE

Rebecca Albrow, Technical Analyst, Diagnostics Assessment Programme, NICE

Robert Fernley, Project Manager, Diagnostics Assessment Programme, NICE

PART 1 AND PART 2 (open and closed parts of the meeting) 10.00am – Part 1 open session commenced

(3)

 Welcomed Committee Members, observers and members of public.

 Rehearsed Committee Apologies

 Farewell to Marlon Hope Project Manager in MTEP taking on Service Delivery Management role for the NICE website and digital applications

 Welcome to Liesl Miller new Technical Analyst in MTEP

2. Code of conduct for members of the public attending the meeting

The Chairman explained the code of conduct to the members of the public attending this meeting.

3. Any other business

No other business was offered.

4. Minutes of previous meeting

The Committee agreed the minutes from the 19 February 2015 Committee meeting.

5. NICE’s advisory body guide to declaring a conflict of interest

The Chairman drew the Committee’s attention to NICE’s Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

6. MT241 UroLift System for the treatment of symptoms of urinary outflow obstruction secondary to benign prostatic hyperplasia – Draft Guidance

Mr Andrew Thorpe and Mr Neil Barber declared a personal pecuniary non-specific interest for this technology.

The Chair clarified that Prof Thomas McNicholas has a personal pecuniary specific interest in this technology

The Committee was asked if there were any specific equality issues to consider in relation to this technology.

Introduced by Paul Knox, Andrew Thorpe and Neil Barber.

11:45 – Part 2 closed session commenced (members of the public asked to leave the meeting)

The Committee then made draft recommendations on the technology.

12:25 – break 12:30 – Meeting resumed

7. MT262 VACOped for the management of Achilles tendon rupture

(4)

The Committee was asked if there were any specific equality issues to consider in relation to this technology.

Introduced by Daniel Clark, Nicola Maffuli and Maneesh Bhatia.

The Committee then considered the technology for selection and routing.

13:05 – Lunch break 13:30 – Meeting resumed

8. MT261 The TearLab osmolarity system for the diagnosis of dry eye disease

No conflicts were declared for this technology.

The Committee was asked if there were any specific equality issues to consider in relation to this technology.

Introduced by Rory O’Connor and Sajjad Ahmad.

The Committee then considered the technology for selection and routing.

13:45 – break 13:50 – Meeting resumed

9. MT263 Granulox for the treatment of chronic wounds

Ms Joy Tickle and Mr Ray Norris declared a personal pecuniary interest for this technology.

The Committee was asked if there were any specific equality issues to consider in relation to this technology.

Introduced by Allan Wailoo, Joy Tickle and Ray Norris.

The Committee then considered the technology for selection and routing.

14:40 – Meeting resumed

10. MT264 The WavSTAT 4 optical biopsy system for the real time histological assessment of colon polyps in vivo

Prof Venkataraman Subramanian declared a non-personal interest for this

technology. Dr James East declared a personal pecuniary and non-personal interest for this technology.

The Committee was asked if there were any specific equality issues to consider in relation to this technology.

Introduced by Brian Selman, Venkataraman Subramanian and James East. The Committee then considered the technology for selection and routing.

(5)

11. Date of the next meeting

The next meeting of the Medical Technologies Advisory Committee will be held on 16 April 2015 and will start promptly at 10:00am. The meeting will be held at the NICE Manchester offices, Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BT.

References

Related documents

Evaluate Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in the Preventive Treatment of Chronic Migraine (TMS-CHROMIG); Study type: Randomized Clinical

The NHS and local government are under very considerable financial pressure, but by following NICE guidance and using our evidence services, NICE can help ensure that

A case series of 300 patients (300 eyes) who had type I corneal graft– keratoprosthesis implantation reported an overall retention rate (defined as anatomical retention at the

People with MS and TN need this procedure to be available as they may not be able to tolerate medication or have surgery without risking relapse or MS symptoms worsening. Are

Qualitative and Quantitative Research Consultant (2012 - 2013) Washington University of St Louis, Brown School of Social Work. Preventing Conduct Disorder among Children in the

NICE Technology appraisal guidance 312 recommends alemtuzumab as an option for treating adults with active relapsing–remitting multiple sclerosis.. NICE Technology appraisal

Accreditation Mark in relation to that accreditation shall terminate with immediate effect, including in relation to information that was produced under accredited processes

Infliximab has a UK marketing authorisation for the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to